인뮨 바이오INMB 주가

♻️ 재탕INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform

Boca Raton, FL - INmune Bio Inc. , a clinical - stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in...

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro™ (XPro1595, pegipanermin) in patients with mild Alzheimer’s disease characterized by bioma

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XPro™ (pegipanermin), the company's first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer's disease (AD). The designation specifically covers XPro™ for treatment of early Alzheimer's disease encompassing both m

[8-K] 중대 사건 — CURRENT REPORT

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnology company developing treatments that harness the patient’s innate immune system to fight disease, today announced it has been named a founding member of the American Biotech Innovation Alliance (ABIA). The newly launched national coalition brings together biotechnology leaders with the shared obje

INmune Bio (INMB) Q1 2026 Earnings Transcript

Need a quote from a Motley Fool analyst? David Moss: Thank you, Daniel, and good afternoon, everyone. For our first quarter 2026 earnings call, today, I'll review key takeaways and provide an update on our platform programs.

♻️ 재탕INmune Bio, Inc. Q1 2026 Earnings Call Summary

Moby summary of INmune Bio, Inc.'s Q1 2026 earnings call

♻️ 재탕INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript

INmune Bio Inc. (INMB) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsDaniel Carlson - Head of Investor RelationsDavid Moss - President,...

Transcript : INmune Bio Inc., Q1 2026 Earnings Call, May 07, 2026

Presentation Operator MessageOperator Greetings, and welcome to the INmune Bio's 2026 First Quarter Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within

INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum

INmune Bio (INMB) reported Q1 2026 EPS of -$0.20, beating estimates by a penny. Stock surged 14.3% last week on pipeline optimism for Alzheimer’s and cancer treatments.